专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US6147204A Nucleic acid ligand complexes 失效
标题翻译：核酸配体配合物
公开(公告)号：US6147204A
公开(公告)日：2000-11-14
申请号：US945604
申请日：1997-10-28
申请人： Larry Gold , Paul G Schmidt , Nebojsa Janjic
发明人： Larry Gold , Paul G Schmidt , Nebojsa Janjic
IPC分类号： A61K9/127 , C07B61/00 , C07H19/06 , C07H19/10 , C07H21/00 , C07K14/00 , C12N9/12 , C12N15/10 , C12Q1/37 , C12Q1/68 , C12Q1/70 , F02B75/02 , G01N33/531 , G01N33/532 , G01N33/535 , G01N33/569 , G01N33/68 , G01N33/76 , C07H21/02 , C07H21/04 , C12P19/34
CPC分类号： A61K9/1271 , A61K47/48076 , A61K47/48092 , A61K9/1272 , C07H19/06 , C07H19/10 , C07H21/00 , C07K14/001 , C12N15/1048 , C12N15/115 , C12N9/1276 , C12Q1/37 , C12Q1/6804 , C12Q1/6811 , C12Q1/6876 , C12Q1/70 , G01N33/531 , G01N33/532 , G01N33/535 , G01N33/56988 , G01N33/68 , G01N33/76 , C12N2310/13 , C12N2310/322 , C12N2310/53 , C40B40/00 , F02B2075/027 , G01N2333/163 , G01N2333/575 , G01N2333/62 , G01N2333/8125 , G01N2333/96433 , G01N2333/96436 , G01N2333/96455 , G01N2333/96486 , G01N2333/966 , G01N2333/9726 , G01N2333/974 , G01N2333/976
摘要： This invention discloses a method for preparing a therapeutic or diagnostic complex comprised of a nucleic acid ligand and a lipophilic compound or non-immunogenic, high molecular weight compound by identifying a nucleic acid ligand by SELEX methodology and associating the nucleic acid ligand with a lipophilic compound or a non-immunogenic, high molecular weight compound. The invention further discloses complexes comprising one or more nucleic acid ligands in association with a lipophilic compound or non-immunogenic, high molecular weight compound.
摘要翻译： PCT No.PCT / US96 / 06171 Sec。 371日期1997年10月28日第 102（e）1997年10月28日PCT PCT 1996年5月2日PCT公布。公开号WO96 / 34876 日期1996年11月7日本发明公开了一种由核酸配体和亲脂性化合物或非免疫原性高分子量化合物组成的治疗或诊断复合物的方法，通过SELEX方法鉴定核酸配体并将核酸配体与亲脂性化合物或非免疫原性高分子量化合物。本发明还公开了包含一种或多种与亲脂性化合物或非免疫原性高分子量化合物结合的核酸配体的复合物。

2. 发明授权

US6011020A Nucleic acid ligand complexes 失效
公开(公告)号：US6011020A
公开(公告)日：2000-01-04
申请号：US434465
申请日：1995-05-04
申请人： Larry Gold , Paul G. Schmidt , Nebojsa Janjic
发明人： Larry Gold , Paul G. Schmidt , Nebojsa Janjic
IPC分类号： A61K9/127 , C07B61/00 , C07H19/06 , C07H19/10 , C07H21/00 , C07K14/00 , C12N9/12 , C12N15/10 , C12N15/115 , C12Q1/37 , C12Q1/68 , C12Q1/70 , F02B75/02 , G01N33/531 , G01N33/532 , G01N33/535 , G01N33/569 , G01N33/68 , G01N33/76 , C07H21/04 , A61K31/70 , C07H21/02
CPC分类号： C12N15/115 , A61K47/48076 , A61K47/48092 , A61K9/1271 , A61K9/1272 , C07H19/06 , C07H19/10 , C07H21/00 , C07K14/001 , C12N15/1048 , C12N9/1276 , C12Q1/37 , C12Q1/6804 , C12Q1/6811 , C12Q1/6876 , C12Q1/70 , G01N33/531 , G01N33/532 , G01N33/535 , G01N33/56988 , G01N33/68 , G01N33/76 , C12N2310/13 , C12N2310/322 , C12N2310/53 , C40B40/00 , F02B2075/027 , G01N2333/163 , G01N2333/575 , G01N2333/62 , G01N2333/8125 , G01N2333/96433 , G01N2333/96436 , G01N2333/96455 , G01N2333/96486 , G01N2333/966 , G01N2333/9726 , G01N2333/974 , G01N2333/976
摘要： This invention discloses a method for preparing a therapeutic or diagnostic complex comprised of a nucleic acid ligand and a lipophilic compound or non-immunogenic, high molecular weight compound by identifying a nucleic acid ligand by SELEX methodology and associating the nucleic acid ligand with a lipophilic compound or a non-immunogenic, high molecular weight compound. The invention further discloses complexes comprising one or more nucleic acid ligands in association with a lipophilic compound or non-immunogenic, high molecular weight compound.

3. 发明授权

US5328678A Composition and method of use for liposome encapsulated compounds for neutron capture tumor therapy 失效
标题翻译：用于中子捕获肿瘤治疗的脂质体包封的化合物的组合物和方法
公开(公告)号：US5328678A
公开(公告)日：1994-07-12
申请号：US998886
申请日：1992-12-28
申请人： Gary Fujii , Paul G. Schmidt , Ronald C. Gamble
发明人： Gary Fujii , Paul G. Schmidt , Ronald C. Gamble
IPC分类号： A61K9/127 , A61K9/133 , A61K41/00 , A61K51/12 , A61K43/00
CPC分类号： A61K51/1234 , A61K41/009 , A61K41/0095 , A61K9/127 , A61K2121/00
摘要： Liposomes with hyperosmotic concentration of compounds encapsulated therein are targeted to tumors for neutron capture therapy. The compounds have an element with a large neutron capture cross section and an isotope that emits alpha particles when bombarded with neutrons. A method employing such liposomes for neutron capture therapy is also described.
摘要翻译：其中封装有高渗透浓度的化合物的脂质体靶向肿瘤用于中子捕获治疗。这些化合物具有大的中子捕获截面的元素和当用中子轰击时发射α粒子的同位素。还描述了使用这种脂质体进行中子捕获治疗的方法。

4. 发明授权

US4728575A Contrast agents for NMR imaging 失效
标题翻译： NMR成像对比剂
公开(公告)号：US4728575A
公开(公告)日：1988-03-01
申请号：US720954
申请日：1985-04-10
申请人： Ronald C. Gamble , Paul G. Schmidt
发明人： Ronald C. Gamble , Paul G. Schmidt
IPC分类号： A61B10/00 , A61B5/05 , A61B5/055 , A61K20060101 , A61K39/395 , A61K49/00 , A61K49/18 , A61K51/00 , G01N24/08 , G01N33/483 , G01R33/28 , B32B5/16
CPC分类号： G01R33/5601 , A61K49/1812
摘要： An agent for contrast enhancement in nuclear magnetic resonance imaging is disclosed. Micellular particles such as phospholipid vesicles are associated with or enclose a paramagnetic material. The particles may be formulated with an agent, such as cholestrol, to promote vesicle stability and water exchange across the vesicle bilayer. The vesicles may or may not have antibodies or other cell recognition targeting agents attached to the surface to provide specific targeting. The vesicles provide enhanced target specificity, reduced burden of toxic contrast material and amplified contrast enhancement.
摘要翻译：公开了核磁共振成像中的对比度增强剂。诸如磷脂囊泡的胶束颗粒与顺磁材料相关联或包围顺磁性材料。可以用诸如胆甾醇之类的试剂配制颗粒，以促进囊泡稳定性和穿过囊泡双层的水交换。囊泡可以具有或可以不具有连接到表面上的抗体或其它细胞识别靶向剂以提供特异性靶向。囊泡提供增强的靶特异性，减少有毒对比材料的负担和放大的对比度增强。

5. 发明授权

US06465188B1 Nucleic acid ligand complexes 失效
标题翻译：核酸配体配合物
公开(公告)号：US06465188B1
公开(公告)日：2002-10-15
申请号：US09569572
申请日：2000-05-10
申请人： Larry Gold , Paul G Schmidt , Nebojsa Janjic
发明人： Larry Gold , Paul G Schmidt , Nebojsa Janjic
IPC分类号： C12Q168
CPC分类号： G01N33/76 , A61K9/1271 , A61K9/1272 , A61K47/547 , A61K47/549 , C07H19/06 , C07H19/10 , C07H21/00 , C07K14/001 , C12N9/1276 , C12N15/1048 , C12N15/115 , C12N2310/13 , C12N2310/322 , C12N2310/53 , C12Q1/37 , C12Q1/6811 , C40B40/00 , F02B2075/027 , G01N33/531 , G01N33/532 , G01N33/535 , G01N33/56988 , G01N33/68 , G01N2333/163 , G01N2333/575 , G01N2333/62 , G01N2333/8125 , G01N2333/96433 , G01N2333/96455 , G01N2333/966 , G01N2333/9726 , G01N2333/974 , G01N2333/976 , C12Q2541/101 , C12Q2563/161
摘要： This invention discloses a method for preparing a therapeutic or diagnostic complex comprised of a nucleic acid ligand and a lipophilic compound or non-immunogenic, high molecular weight compound by identifying a nucleic acid ligand by SELEX methodology and associating the nucleic acid ligand with a lipophilic compound or a non-immunogenic, high molecular weight compound. The invention further discloses complexes comprising one or more nucleic acid ligands in association with a lipophilic compound or non-immunogenic, high molecular weight compound.
摘要翻译：本发明公开了一种由核酸配体和亲脂性化合物或非免疫原性高分子量化合物组成的治疗或诊断复合物的方法，其通过使用SELEX方法鉴定核酸配体并将核酸配体与亲脂性化合物或非免疫原性的高分子量化合物。本发明进一步公开了包含与亲脂性化合物或非免疫原性高分子量化合物结合的一种或多种核酸配体的复合物。

6. 发明授权

US06412601B1 Ladder pan 有权
标题翻译：梯子盘
公开(公告)号：US06412601B1
公开(公告)日：2002-07-02
申请号：US09521077
申请日：2000-03-07
申请人： Paul G. Schmidt
发明人： Paul G. Schmidt
IPC分类号： E04G100
CPC分类号： E06C7/14
摘要： A suspendible container for holding items that is capable of being attached to holes on a horizontal surface. The container is particularly adaptable to being attached to the top cap of a ladder. The container includes at least one prong which attaches to the container and is removably insertable into a hole in the horizontal surface. The container is particularly suited for holding items such as tools and paint cans that would be needed by the user of a ladder.
摘要翻译：用于容纳能够附着在水平表面上的孔的物品的可悬挂容器。该容器特别适合于附接到梯子的顶盖上。容器包括至少一个尖头，其附接到容器并且可移除地插入到水平表面中的孔中。容器特别适用于容纳梯子用户需要的诸如工具和油漆罐的物品。

7. 发明授权

US5320906A Delivery vehicles with amphiphile-associated active ingredient 失效
标题翻译：运送车辆与两亲相关的活性成分
公开(公告)号：US5320906A
公开(公告)日：1994-06-14
申请号：US842271
申请日：1991-12-20
申请人： Crispin G. S. Eley , Paul G. Schmidt , Gary Fujii
发明人： Crispin G. S. Eley , Paul G. Schmidt , Gary Fujii
IPC分类号： A61K9/127 , A61K9/133 , A61K47/48 , A61K49/18
CPC分类号： A61K9/1277 , A61K47/48053 , A61K47/48815 , A61K49/1812 , Y10S436/829 , Y10T428/2984 , Y10T436/24
摘要： Delivery vehicles comprising an outer biocompatible encapsulating layer, an inner amphiphilic active ingredient-associated layer and an active ingredient are described. The delivery vehicles are biocompatible and are capable of solubilizing the active ingredient for in vivo delivery to bodily tissue or other bodily systems. Uses include nuclear magnetic resonance imaging and therapeutic drug delivery.
摘要翻译：描述了包含外部生物相容性封装层，内部两亲活性成分相关层和活性成分的递送载体。递送载体是生物相容的并且能够增溶活性成分用于体内递送到身体组织或其他身体系统。用途包括核磁共振成像和治疗药物递送。

8. 发明授权

US5817334A Method of making liposomes with improved stability during drying 失效
标题翻译：制备干燥时稳定性好的脂质体的方法
公开(公告)号：US5817334A
公开(公告)日：1998-10-06
申请号：US469156
申请日：1995-06-06
申请人： Paul G. Schmidt , Gary Fujii
发明人： Paul G. Schmidt , Gary Fujii
IPC分类号： A61K9/127 , A61K47/26 , A61K47/42 , B01J13/02 , A61K9/10
CPC分类号： A61K9/1277 , A61K9/127 , Y10S436/829
摘要： A composition and method are provided for the making of cholesterol containing phospholipid liposomes such that when dried and then reconstituted, the liposomes retain their structure and size distribution as well as substantially all of the material that was originally encapsulated, and they behave biologically in a normal fashion. The cryoprotective agents are used in the aqueous medium to hydrate the phospholipid(s) and are a combination of at least one sugar and at least one protein, polypeptide, and/or oligopeptide.
摘要翻译：提供了一种用于制备含胆固醇的磷脂脂质体的组合物和方法，使得当干燥然后重构时，脂质体保留其结构和尺寸分布以及基本上所有原始包封的材料，并且它们在正常情况下表现为生物学时尚。在水性介质中使用冷冻保护剂来水合磷脂，并且是至少一种糖和至少一种蛋白质，多肽和/或寡肽的组合。

9. 发明授权

US5258499A Liposome targeting using receptor specific ligands 失效
标题翻译：使用受体特异性配体的脂质体靶向
公开(公告)号：US5258499A
公开(公告)日：1993-11-02
申请号：US850019
申请日：1992-03-10
申请人： Paula J. Konigsberg , Leroy L. Richer , Paul G. Schmidt , Joseph A. Uliana
发明人： Paula J. Konigsberg , Leroy L. Richer , Paul G. Schmidt , Joseph A. Uliana
IPC分类号： A61K9/127 , A61K47/48 , A61K37/02 , C07K3/08 , C07K15/08
CPC分类号： A61K9/1271 , A61K47/48815
摘要： Delivery vehicle formulations comprise active agents encapsulated within liposomal vesicles to which are attached protein hormones (ligands) such as interleukin-2. The ligands are capable of showing affinity for specific cell receptors resulting in delivery of the encapsulated active agent to target cells, enabling delivery of active agents to particular cell populations in the treatment of conditions such as immune system disorders.
摘要翻译：递送载体制剂包含包封在脂质体囊泡内的活性剂，其与蛋白激素（配体）如白细胞介素-2连接。配体能够显示对特定细胞受体的亲和力，导致将包封的活性剂递送至靶细胞，使活性剂能够在治疗诸如免疫系统疾病的病症中传递给特定的细胞群体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式